Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 12/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23091745 | 1.00 | NPC1 (0.47) | NPC1RAB9AALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL23091719 | 0.89 | RAB9A (0.50) | NPC1RAB9AALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL29687405 | 0.87 | RAB9A (0.53) | NPC1RAB9AALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL23091691 | 0.87 | RAB9A (0.53) | NPC1RAB9AALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL23091767 | 0.85 | MAPT (0.46) | ABL1MAPT | |
| SCHEMBL29687786 | 0.85 | MAPT (0.46) | ABL1MAPT | |
| SCHEMBL23091708 | 0.84 | TRPV1 (0.47) | NPC1RAB9AALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL29687203 | 0.84 | ABL1 (0.48) | ABL1 | |
| SCHEMBL23091717 | 0.84 | ABL1 (0.48) | ABL1 | |
| SCHEMBL23091694 | 0.83 | MAPT (0.45) | ABL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4028387-A1 | NEW COMPOUNDS AND METHODS | BenevolentAI Bio Limited (GB) | 2022-07-20 | — | — | EP | claimed |
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | BenevolentAl Bio Limited (GB) | 2023-01-05 | — | — | US | disclosed |
| EP-4028387-A1 | NEW COMPOUNDS AND METHODS | BenevolentAI Bio Limited (GB) | 2022-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | NPC1 333/4885RAB9A 1661/4885ALDH1A1 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.